Wednesday, May 18, 2022

Cassava Sciences Stock Soared 130% on Monday Followed by Positive Results of New Alzheimer’s Phase 2 Trials

The biotech company Cassava Sciences updates that its Alzheimer’s drug, sumifilam, recorded positive results in treating Alzheimer’s patients in a phase 2 study.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


Cassava Sciences Inc. (SAVA) shares were on a roll in the last trading session on Monday after the company reported that it has obtained positive outcomes from its Phase 2 study of a new Alzheimer drug, sumifilam (PTI-125). The company will keep up the development work on sumifilam unless it obtains the optimum outcome that is required to treat Alzheimer patients. 


A Backdoor Way To Profit From Today’s Crypto Bull Market

Even if you’re not actively in crypto, you deserve to know what’s actually going on...

Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.

Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .

Sponsored


The stock price surged massively crossing $8.11 price since mid-March and from then on, the price started to drop as the COVID-19 pandemic had a massive adverse influence at that time. 

After closing around $3.32 on Friday, SAVA shares soared whoppingly to $6.45 as of 9:30 A.M. EDT on September 11. The shares kept on rising reaching at days highest of $8.17 at 03:15 P.M. on September 14. The investors were happy from Cassava’s development and showed trust in the company hoping for promising end results. 

However, there is a lot of work to do on sumifilam before it gets its final approval but that is not what concerns at the moment. The thing that attracts the investors is the spike in implied volatility in the stock. 

The key here for Cassava Sciences is that it has not many competitors in the market working on Alzheimer’s treatments. The only notable firm working on Alzheimer’s treatments is Biogen, but if Cassava makes a breakthrough in final trials it would be the only company with AD therapy.

Earlier in May, the company could not obtain the desired results from the Phase 2 trials and failed to achieve the primary endpoint. At that time, Cassava reported high variability in biomarker data in the control group, which was against the pre-defined endpoints. 

These positive outcomes have come from the Phase 2b clinical study which was funded by the National Institutes of Health (NIH). The company will present Phase 2 data of sumifilam at H.C. Wainwright’s 22nd Annual Global Investment Conference.  The founder and CEO of Cassava Sciences said:

“We feel that this is a drug that finally can offer some real hope to patients who have Alzheimer’s, as well as people who have a family history of Alzheimer’s. Up until now, there really has been very very little hope for these patients.”

The Phase 2 data showed that treatment with sumifilam recorded statistically significant improvements in a range of AD-related biomarkers in comparison to the placebo, the primary endpoint. The response rate was 98%, defined as patients who showed biomarker improvements. Sumifilam was reported as a safe drug and was well-tolerated. 

It is reported that almost 5 million Americans are suffering from Alzheimer’s disease and the treatment method so far is little known and currently has no impactful treatment. Suffering from Alzheimer’s disease can be scary and painful. If Cassava Sciences Inc. (SAVA) can bring sumifilam to market as an effective solution for Alzheimer’s patients it could bring in millions of dollars to SAVA’s sales. 

Latest news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

Related news

A Few Bright Spots in Tesla Inc. (TSLA)

Tesla's (TSLA) Shanghai facility ceased operations on Monday owing to material shortages, according to Reuters. Furthermore, demand for Tesla electric vehicles decreased drastically in...

A Closer Look at DocuSign Inc.’s (DOCU) Growth Curve

DocuSign Inc. (NASDAQ: DOCU), a software firm that creates an electronic signature and verification solutions, is presently trading more than 70% below its 52-week...

One Of The Good Ones: Enphase Energy Inc. (ENPH)

Enphase Energy, Inc. (NASDAQ: ENPH), a maker of inverters, released its first-quarter 2022 results. Enphase set a new sales record and outperformed Wall Street...

Riding the Trend or Protecting Profits | AT&T Inc. (T)

AT&T Inc. (NYSE: T), a telecommunications service provider, released its first-quarter earnings last week. The firm claimed a record number of new communication subscribers,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

1745

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam